Health watchdog for UK up and running:
This article was originally published in Clinica
Executive Summary
The UK Commission of Health Improvement (CHI) has started work as an independent standards watchdog for the National Health Service (NHS). The CHI will monitor the quality of care within the NHS and review every hospital and primary care group in England and Wales within the next four years. The first specialty area to be reviewed will be cancer services, followed by coronary heart disease and mental health. Evidence from the reviews, which are set to start from next May, will be published on the Internet. The CHI will also work closely with the National Institute of Clinical Excellence (NICE) and monitor the quality of care throughout the NHS.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.